Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
Open Access
- 28 March 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 17 (6), 626-635
- https://doi.org/10.1016/s1473-3099(17)30171-8
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Evaluating the Pharmacodynamic Effect of Antimalarial Drugs in Clinical Trials by Quantitative PCRAntimicrobial Agents and Chemotherapy, 2015
- Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort studyThe Lancet Infectious Diseases, 2015
- Direct evidence for the atovaquone action on the Plasmodium cytochrome bc 1 complexParasitology International, 2015
- Quantification of female and male Plasmodium falciparum gametocytes by reverse transcriptase quantitative PCRMolecular and Biochemical Parasitology, 2015
- Optimal dose finding for novel antimalarial combination therapy*Tropical Medicine & International Health, 2012
- A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720PLOS ONE, 2011
- A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial DrugsPLOS ONE, 2011
- A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteersMalaria Journal, 2011
- Changes in health workers' malaria diagnosis and treatment practices in KenyaMalaria Journal, 2011
- Combination Therapy for MalariaDrugs, 2002